Test Your Knowledge: Pharma Development & Outsourcing Innovation

Published on: March 2, 2026

The following 10 questions will evaluate your knowledge of integrated CDMO models, multivariate analytics, and the role of AI governance in decision-making. As the industry shifts toward shared risk ownership and decision quality, staying informed on these trends is essential for building resilient, data-transparent partnerships that accelerate timelines and reduce late-stage risks.

In Febuary 2026, Katie Edgar, chief business officer, KBI Biopharma, discussed “How Innovation Is Reshaping Outsourced Development and Manufacturing” with PharmTech. See how much you know about the topic; be sure to click through at the end to see the answers!

1. To ensure seamless scale transitions and mitigate regulatory continuity risks, what range of bioreactor capacities is typically cited as essential for a modern biologics manufacturing facility?

A. 100 to 500 liters
B. 1,000 to 15,000 literS
C. 50 to 250 liters
D. 20,000 to 50,000 liters

2. According to the FDA, what is the “hallmark” of the Emerging Technology Program designed to support innovative manufacturing?

A. Provision of federal grants to small biotechs developing novel mRNA delivery systems.
B. Early engagement between the industry and the cross-functional Emerging Technology team.
C. Elimination of onsite inspections for facilities using single-use bioreactor systems.
D. Automatic approval for any application utilizing AI-driven process modeling.

3. In the context of Explainable AI, what is the defining characteristic of post-hoc explainability techniques like SHAP (SHapley Additive exPlanations) and LIME (Local Interpretable Model-agnostic Explanations)?

A. They are used to train inherently transparent models, such as decision trees, from the start.
B. They guarantee that a deep learning model will reach 100% predictive accuracy.
C. They eliminate the need for human subject matter experts in the governance framework.
D. They provide insights into the internal logic of a model after it has already been trained.

4. How do advanced analytics and process modeling improve decision quality during the early stages of drug development?

A. By replacing experimental design with purely theoretical simulations to save costs.
B. By providing a “black-box” output that requires no interpretation from technical teams.
C. By ensuring that clinical trial enrollment rates remain static regardless of market conditions.
D. By allowing teams to test assumptions and evaluate scale-up feasibility before downstream commitments are locked in.

5. The manufacturing of antibody-drug conjugates (ADCs) is cited as a primary example of which industry trend?

A. The shift toward using only large-scale 15,000-liter stainless steel bioreactors.
B. The return to traditional small-molecule manufacturing paradigms.
C. The complete automation of drug delivery systems without human oversight.
D. The convergence of biologics- and chemistry-driven manufacturing processes.

6. Which of the following describes the “Three S” principles that serve as the operational foundation for collaborative CDMO partnerships?

A. Simplification, standardization, and scalability
B. Specialization, secrecy, and solvency
C. Speed, security, and sustainability
D. Sourcing, synthesis, and stability

7. Under the FDA's Emerging Technology Program, when does a specific technology 'graduate' from the program?

A. When the technology is replaced by a newer, more innovative manufacturing method.
B. As soon as the first clinical trial associated with the technology is completed.
C. When the company receives its first $100 million in commercial revenue.
D. When the FDA and the industry have gained sufficient experience with the technology.

8. Why is “digital maturity” becoming a key criterion for biotech leaders when selecting a CDMO partner?

A. It allows for the use of digital twins and predictive analytics to optimize processes and maintenance.
B. It ensures that the CDMO will only use paper-based documentation to prevent cyberattacks.
C. It focuses solely on social media presence to attract clinical trial participants.
D. It eliminates the need for regulatory inspections by automating compliance reports.

9. What is the primary motivation for CDMOs to invest in workforce and facility capacity ahead of projected demand?

A. To ensure that all manufacturing processes remain at the 200-liter lab scale.
B. To increase the total carbon footprint of the facility for tax incentives.
C. To mitigate the lag between clinical approval and market launch, ensuring supply continuity.
D. To comply with the EU's “right to explanation” regulation regarding AI.

10. In the context of CDMO evolution, what does the “single source of truth” concept refer to?

A. The idea that only small biotechs have accurate data for early-stage development.
B. A marketing slogan used to promote the acquisition of CROs by larger pharma companies.
C. A regulatory requirement that only one person is allowed to sign off on batch records.
D. A shared data platform that integrates development, clinical research, and manufacturing information.